Efficacy Study of Levocarnitine Adjuvant Therapy for Complications of Heart Failure

Abstract

The objective is to investigate the role of standard treatment combined with Levocarnitine (LC) in improving clinical outcomes in patients with complications of heart failure. The authors collected and organized data from 700 patients with complications of heart failure admitted to our cardiology department from January 2015 to February 2020. The patients were divided into a control group and an LC group, with 350 cases in each group. The control group received standard treatment, while the LC group received standard treatment combined with LC. The authors compared left ventricular ejection fraction (LVEF) and brain natriuretic peptide (BNP) levels between the two groups. Results: The LVEF level in the LC group was higher than that in the control group after treatment, with P<0.05. The BNP levels were similar between the two groups after treatment, with P>0.05. In the LC group, the LVEF level in patients with heart failure and diabetes was higher than that in the control group, and the BNP level was lower than that in the control group, with P<0.05. In patients with heart failure and atrial fibrillation in the LC group, the LVEF level was higher than that in the control group (P<0.05), and the BNP levels were similar between the two groups (P>0.05) after treatment. In patients with heart failure and dilated cardiomyopathy in the LC group, the LVEF level was higher than that in the control group, and the BNP level was lower than that in the control group, with P<0.05. Conclusion: LC combined with standard treatment can more significantly improve LVEF and BNP levels in patients with complications of heart failure, especially in the subgroup of heart failure with diabetes.